Zevtera: a new cephalosporin antibiotic

Basilea has launched Zevtera (ceftobiprole), a new intravenous antibiotic for the treatment of pneumonia.

Ceftobiprole (Zevtera) is active against multiple pathogens, including MRSA.
Ceftobiprole (Zevtera) is active against multiple pathogens, including MRSA.

Zevtera (ceftobiprole) is a broad-spectrum cephalosporin antibiotic indicated for the treatment of community- and hospital-acquired pneumonia (excluding ventilator-associated pneumonia).

Further information
View Zevtera drug record 
Summary of Product Characteristics
Manufacturer: Basilea

Ceftobiprole medocaril sodium, the active ingredient of Zevtera, is the prodrug of ceftobiprole. Similar to other beta lactams, ceftobiprole is bactericidal and works by binding to penicillin-binding proteins in susceptible species, inhibiting synthesis of the peptidoglycan cell wall. Ceftobiprole is inactive against Enterobacteriaceae, Acinetobacter and P. aeruginosa strains that express β-lactamases of Ambler class A, B or D. 

Ceftobiprole is administered as a 500mg intravenous infusion over 2 hours every 8 hours. In community-acquired pneumonia it may be suitable to switch the patient to an oral antibiotic after at least 3 days of ceftobiprole treatment, depending on their response. 

The most common adverse effects of ceftobiprole are nausea, vomiting, diarrhoea, infusion site reactions, hypersensitivity and dysgeusia.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more